LRRC8A and ischemic stroke: Current therapies for ischemic stroke are limited to tissue plasminogen activators and endovascular thrombectomy.[6, 46] Clinical trials for stroke focusing on single disease mechanisms are often considered insufficient to suppress the ischemic cascades.[7] Here, we report that the SWELL1 channel plays a dual role in the pathogenesis of ischemic stroke, representing a promising target for this devastating disease.